Name
RF01-08 - A randomized, open-label phase III trial Evaluating Low-Dose Vs standard-dose Olanzapine with triple Antiemetic therapy for Prevention of highly emetogenic chemotherapy- induced Nausea and vomiting in solid tumors (OLAnzaPiNE) (China)
Date & Time
Wednesday, December 20, 2023
Speakers
Virtual Session Link